Login
$VTGN
$0.17 -$0.01 (6.57%) After hours

$VTGN SEC Filings

Filed On Filing
13 Nov 2026 10-Q
13 Nov 2026 8-K: Results of Operations and Financial Condition

Advancing potential to execute Phase 3 development plan for fasedienol in social anxiety disorder following constructive FDA feedback, with disciplined capital management and strategic flexibility

09 Nov 2026 8-K: Other Events

Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder

30 Oct 2026 8-K: Costs Associated with Exit or Disposal Activities; Other Events

On October 26, 2026, Vistagen Therapeutics, Inc. (the “Company”) implemented a Board-approved reduction in workforce by approximately 31%, retaining core clinical, regulatory, technical, and corporate capabilities required for U.S. regis...

09 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

1. Purpose. The Board of Directors of Vistagen Therapeutics, Inc. (the “Board”), a Nevada corporation (“Vistagen” or the “Company”), recognizes that a potential involuntary termination of employment of Vistagen’s senior management, inclu...

25 Sep 2026 8-K: Regulation FD Disclosure

1 Nasdaq: VTGN Corporate Presentation Harnessing the therapeutic power and potential of brain regulation with nose-to-brain neurocircuitry September 2026

24 Sep 2026 8-K: Other Events

Exploratory research results presented at Psych Congress 2026 in New Orleans

22 Sep 2026 8-K: Other Events

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

11 Sep 2026 8-K: Submission of Matters to a Vote of Security Holders

On September 10, 2026, Vistagen Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). At the 2026 Annual Meeting, as set forth below, the Company’s stockholders: (i) elected each of ...

14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 10-Q
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 8-K: Results of Operations and Financial Condition

Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies

06 Aug 2026 8-K: Regulation FD Disclosure; Other Events

Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose

05 Aug 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On August 4, 2026, Vistagen Therapeutics, Inc. (the “Company”) received an extension notification (the “Extension Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“Nasdaq”) granting the Company a 180-day ex...

31 Jul 2026 DEFA14A
31 Jul 2026 Proxy statement: annual meeting on September 10, 2026

CEO pay $1.2M, down 51% · say-on-pay vote

31 Jul 2026 Form 4: Williamson Douglas J, Director

Granted 40,826 Stock Options (Right to Buy)

31 Jul 2026 Form 3: Williamson Douglas J, Director

No securities owned

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support